Tempest Therapeutics (TPST) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free TPST Stock Alerts $3.18 -0.04 (-1.24%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12, 2024 | marketbeat.comTempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Increase in Short InterestTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,580,000 shares, a growth of 39.8% from the April 15th total of 1,130,000 shares. Based on an average daily trading volume, of 901,800 shares, the short-interest ratio is presently 1.8 days. Currently, 9.4% of the company's stock are sold short.May 12, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Tempest Therapeutics (NASDAQ:TPST)May 10, 2024 | marketbeat.comTempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research report on Friday.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical AdvancementsMay 10, 2024 | finanznachrichten.deTempest Therapeutics: Tempest Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comTempest Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 26, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 13, 2024 | marketbeat.comTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest UpdateTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 969,700 shares, a growth of 26.5% from the March 15th total of 766,800 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 0.9 days.April 13, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 6.8%April 9, 2024 | markets.businessinsider.comBuy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug DevelopmentsApril 9, 2024 | finance.yahoo.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 9, 2024 | globenewswire.comTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingApril 6, 2024 | uk.investing.comTempest Therapeutics moves TPST-1120 into phase 3 trialApril 4, 2024 | finance.yahoo.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsApril 4, 2024 | globenewswire.comTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsMarch 22, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Tempest Therapeutics, Inc. (NASDAQ:TPST) Issued By HC WainwrightTempest Therapeutics, Inc. (NASDAQ:TPST - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Tempest Therapeutics in a report released on Wednesday, March 20th. HC Wainwright analyst J. Pantginis expects that the company will post earnings ofMarch 21, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Tempest Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TPST)Tempest Therapeutics, Inc. (NASDAQ:TPST - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Tempest Therapeutics in a research report issued on Wednesday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the company wMarch 21, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)March 20, 2024 | finanznachrichten.deTempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | marketbeat.comWilliam Blair Reiterates "Outperform" Rating for Tempest Therapeutics (NASDAQ:TPST)William Blair reaffirmed an "outperform" rating on shares of Tempest Therapeutics in a research report on Wednesday.March 19, 2024 | investorplace.comTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | globenewswire.comTempest Reports Year End 2023 Financial Results and Provides Business UpdateMarch 15, 2024 | marketbeat.comTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Down 17.7% in FebruaryTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 29th, there was short interest totalling 716,500 shares, a decrease of 17.7% from the February 14th total of 870,400 shares. Approximately 4.5% of the shares of the stock are sold short. Based on an average daily volume of 886,000 shares, the short-interest ratio is presently 0.8 days.March 14, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)March 14, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Research Coverage Started at ScotiabankScotiabank initiated coverage on shares of Tempest Therapeutics in a report on Thursday. They issued a "sector outperform" rating and a $13.00 target price for the company.March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial ProspectsMarch 12, 2024 | finance.yahoo.comTempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer TypesMarch 8, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Shares Down 4.9% Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 4.9%March 5, 2024 | globenewswire.comTempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual MeetingFebruary 26, 2024 | finance.yahoo.comTempest to Present at the 44th Annual TD Cowen Healthcare ConferenceFebruary 8, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Receives New Coverage from Analysts at Jefferies Financial GroupJefferies Financial Group started coverage on Tempest Therapeutics in a report on Thursday. They set a "buy" rating and a $15.00 price target on the stock.February 3, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Shares Down 0.7% Tempest Therapeutics (NASDAQ:TPST) Shares Down 0.7%January 30, 2024 | finance.yahoo.comTempest Therapeutics, Inc. (TPST)December 28, 2023 | benzinga.comTempest Therapeutics Stock (NASDAQ:TPST), Short Interest ReportDecember 11, 2023 | benzinga.comTempest Therapeutics Stock (NASDAQ:TPST) Insider TradesDecember 2, 2023 | finanznachrichten.deTempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 1, 2023 | finance.yahoo.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 20, 2023 | finance.yahoo.comTempest to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 11, 2023 | markets.businessinsider.comGrowth Potential and Strategic Partnerships: Reasons for Aydin Huseynov’s Buy Rating on Tempest TherapeuticsNovember 11, 2023 | msn.comTempest Therapeutics (NASDAQ:TPST) Blasts Up on Improved Cash PictureNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Atara Biotherapeutics (ATRA) and Tempest Therapeutics (TPST)November 10, 2023 | markets.businessinsider.comStrong 3Q23 Results and Promising Clinical Developments Reinforce Buy Rating for Tempest TherapeuticsNovember 9, 2023 | msn.comTempest Therapeutics stock rallies in wake of business updateNovember 8, 2023 | finance.yahoo.comTempest Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 1, 2023 | msn.comTempest Therapeutics (TPST) Price Target Increased by 38.30% to 22.10October 21, 2023 | marketbeat.comMarketBeat Week in Review – 10/16 - 10/20 (TPST)All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in controlOctober 17, 2023 | benzinga.comWhat's Going On With Tempest Therapeutics Stock Today?October 17, 2023 | marketbeat.comNavigating the Roller Coaster of Recent Penny Stock Surges (TPST)Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. TPST Media Mentions By Week TPST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼0.970.49▲Average Medical News Sentiment TPST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼22▲TPST Articles Average Week Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HOOK News JAGX News RLYB News SCYX News MRNS News IFRX News ASMB News VTVT News MNOV News DERM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPST) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
